De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials
降低 ONL1204 的风险,为首次人体临床试验提供风险投资
基本信息
- 批准号:9253126
- 负责人:
- 金额:$ 49.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-01 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAge related macular degenerationAnatomyAnimal ModelApplications GrantsAwardBackBiological PreservationBiological SciencesBiotechnologyBlindnessCD95 AntigensCapitalCell DeathCell SurvivalCell physiologyCellsCessation of lifeChronicChronic DiseaseClinicalClinical TrialsCommunitiesDataDevelopmentDevelopment PlansDiabetic RetinopathyDiseaseDoseDrug KineticsDrug PrescriptionsEnvironmentExudative age-related macular degenerationEyeFormulationFundingFutureGoalsGrantHealth Care CostsHomeostasisHumanInjuryInnovative TherapyInterventionInvestmentsLeadLightMediatingMedicalMetabolicMethodologyModelingNeuroprotective AgentsNonexudative age-related macular degenerationOperative Surgical ProceduresOphthalmologyOrphanOrphan DrugsOutcomePathway interactionsPatient-Focused OutcomesPatientsPeptidesPerioperativePharmaceutical PreparationsPhasePhotoreceptorsPhysiciansProductivityProgram DevelopmentRetinaRetinalRetinal DegenerationRetinal DetachmentRetinal DiseasesRiskRodentSafetySecureSeedsSmall Business Innovation Research GrantSocial ImpactsSocietiesStructure of retinal pigment epitheliumTherapeuticTissuesToxicologyTranslatingUnited StatesVisionVisualVisual AcuityWorkclinical developmentcommercial applicationcommercializationcosteconomic impactimprovedinhibitor/antagonistinterestintravitreal injectionmanufacturing scale-upneurotransmissionnovelpreventprogramsrelating to nervous systemrepairedsystemic toxicity
项目摘要
PROJECT SUMMARY / ABSTRACT
Retinal degenerative disease and injury are among the leading causes of irreversible vision loss and
blindness in the United States and the developed world, affecting hundreds of thousands of people every year
and resulting in billions of dollars in added healthcare costs and lost productivity. Photoreceptor cell death is a
consequence of many of these acute and chronic retinal diseases, leading to vision loss, and helping
photoreceptors survive during the period of disease would significantly improve the visual outcomes for
patients. A problem that limits the efficacy of current treatments is the lack of interventions that can specifically
prevent photoreceptor cell death; therefore, a safe and potent photoreceptor protectant would provide a
significant visual benefit to hundreds of thousands of people every year.
ONL1204 is a novel, small peptide inhibitor of Fas-mediated photoreceptors cell death in development
for peri-operative adjunctive use in patients with acute retinal detachment (an orphan indication for which
ONL1204 has received an orphan drug designation) with the goal of preventing photoreceptor cell death until
definitive surgical repair can occur. This acute indication provides a rapid development pathway that lays the
groundwork for future expansion of ONL1204 development for chronic indications, such as age-related
macular degeneration. The product for acute retinal detachment will be a prescription drug administered by
intravitreal injection.
Completion of the proposed studies in this grant will help ONL Therapeutics address final investor
questions and attract the significant financial investment required for IND submission and clinical development
of ONL1204. Specifically, in this grant, we will 1) determine the minimal dose of ONL1204 required for
photoreceptor protection and preservation of function in large eye animal models of retinal detachment, and 2)
demonstrate the GLP safety and tolerability of a single intravitreal injection of ONL1204 at clinically meaningful
doses.
The studies proposed in this application are necessary for development and commercialization of
ONL1204, will de-risk the program, and enable significant financial investment, allowing ONL Therapeutics to
evaluate clinical POC for ONL1204 in retinal detachment.
项目总结/摘要
视网膜变性疾病和损伤是不可逆视力丧失的主要原因之一,
失明在美国和发达国家,每年影响数十万人
并导致数十亿美元的医疗成本增加和生产力损失。感光细胞死亡是一种
许多这些急性和慢性视网膜疾病的后果,导致视力丧失,并帮助
在疾病期间存活的光感受器将显着改善视觉结果,
患者限制当前治疗效果的一个问题是缺乏能够特异性地
防止感光细胞死亡;因此,安全有效的感光细胞保护剂将提供
每年为数十万人带来显著的视觉效益。
ONL 1204是一种新型的Fas介导的光感受器细胞死亡的小肽抑制剂
用于急性视网膜脱离患者的围手术期预防性使用(孤儿适应症,
ONL 1204已获得孤儿药认定),目的是预防感光细胞死亡,
可以进行明确的手术修复。这种急性适应症提供了一种快速发展途径,
为将来扩展ONL 1204开发用于慢性适应症(如年龄相关性)奠定基础
黄斑变性用于治疗急性视网膜脱离的产品将是一种处方药,
玻璃体内注射
完成这项赠款中的拟议研究将有助于ONL Therapeutics解决最终投资者
问题,并吸引IND提交和临床开发所需的大量财务投资
ONL 1204的。具体而言,在本补助金中,我们将1)确定ONL 1204的最小剂量,
视网膜脱离的大眼睛动物模型中的光感受器保护和功能保存,和2)
在临床上有意义的情况下证明ONL 1204的单次玻璃体内注射的GLP安全性和耐受性。
剂量
本申请中提出的研究对于开发和商业化是必要的。
ONL 1204将降低该计划的风险,并实现重大的财务投资,使ONL Therapeutics能够
评价ONL 1204在视网膜脱离中的临床POC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jana van de Goor其他文献
Jana van de Goor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 49.98万 - 项目类别:
Research Grant